News

People with a certain type of genetic makeup who’ve have head trauma may have a risk of developing multiple sclerosis (MS) up to nearly 18 times over those without genetic factors or a history of head trauma, a study shows. “Our study could prompt further research to uncover the…

Problems with the workings of a protein called hnRNP A1 drives nerve death in multiple sclerosis (MS) by affecting how nerve cells process RNA, a study reports. RNA is an intermediary molecule that’s produced when genes are “read,” and it is used as a template for protein production. Abnormalities…

A smartphone application called Floodlight Open may help in tracking areas of function in people with multiple sclerosis (MS), but more work is needed to improve patient adherence to using the app in a real-world setting, according to a new study. Researchers tested Floodlight Open’s use among more than…

A research team at the Kessler Foundation has received a $39,994 grant from the Consortium of Multiple Sclerosis Centers (CMSC) to investigate whether combining aerobic cycling with virtual reality can improve cognitive function in people with multiple sclerosis (MS). A key focus of the study will be to…

A Kessler Foundation research scientist will use a multiyear, $704,054 federal grant to study care barriers, cardiovascular risk factors, and accelerated brain aging in Latino multiple sclerosis (MS) patients, the nonprofit healthcare organization announced in a press release. Cristina A. F. Román, PhD, an investigator with Kessler’s Rocco…

Junctions between nerve cells and certain cells called oligodendrocyte precursor cells, or OPCs, in the brain and spinal cord may play an important role in producing myelin, the protective substance that’s progressively lost in multiple sclerosis (MS), new research suggests. OPCs are abundant in the brain and spinal…

The level of proteins called kappa free light chains in the cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — may be used as a diagnostic marker to identify the presence of primary progressive multiple sclerosis (MS), according to a new study. Testing for…

Fampyra (fampridine), an approved oral treatment to improve the walking abilities of adults with multiple sclerosis (MS), soon will be sold by Acorda Therapeutics worldwide. The announcement follows the decision by Biogen to terminate a licensing agreement that gave it global development and marketing rights…

Mitochon Pharmaceuticals is launching a pilot clinical trial to evaluate MP101, its treatment candidate for improving mitochondrial function, in people with multiple sclerosis (MS) and other neurodegenerative diseases. The announcement follows the trial’s clearance by the European Medicines Agency (EMA), which enables Mitochon to begin enrolling patients with…

Myrobalan Therapeutics has secured $24 million in series A financing to support the development of oral medications for multiple sclerosis (MS) and other diseases of the central nervous system (CNS), which comprises the brain and spinal cord. The company’s pipeline currently includes three candidate therapies…

Genetic changes that predispose people to developing multiple sclerosis (MS) first emerged among herding populations who migrated to Eastern Europe thousands of years ago and then spread across the continent, new research has found. Researchers think these genetic variations may have helped turbocharge the immune system, making it easier…

Engaging in online sessions of compassion-focused therapy, which works toward getting people to become more compassionate about themselves, may help women with multiple sclerosis (MS) deal with suicidal thoughts, a small study suggests. Compassion-focused therapy also may help these women overcome pain catastrophizing, which is a tendency to view…

People with multiple sclerosis (MS) have high levels of T-cells in their spinal fluid that specifically target cells infected with the Epstein-Barr virus (EBV), according to a new study. These T-cells were found in samples collected from patients during their diagnostic workup in the early stages of…

Women with a history of depression around the time they get pregnant are at increased risk of developing autoimmune diseases such as multiple sclerosis (MS), according to recent research. Likewise, women who have an autoimmune disease are more likely to get depressed during pregnancy and in the year after…

Monte Rosa Therapeutics is planning to initiate a Phase 1 clinical trial to test MRT-6160, its investigational therapy for multiple sclerosis (MS) and other autoimmune diseases, by mid-2024. The trial will follow the submission of an investigational new drug (IND) application, a formal request to U.S. regulatory authorities…

Six of eight patients with nonactive secondary progressive multiple sclerosis (SPMS) being treated with foralumab nasal spray — all part of an intermediate-size expanded access program (EAP) allowing the therapy’s use — have experienced reductions in their fatigue levels. That’s according to treatment developer Tiziana Life Sciences,…

The ongoing worsening of disability among people with primary progressive multiple sclerosis (PPMS) may be predicted by elevated blood levels of the GFAP protein, a marker of damage to star-shaped support cells in the brain and spinal cord called astrocytes, a study suggests. The risk of disability progression was…

Daily treatment with CNM-Au8 led to sustained improvements in vision and cognition for people with relapsing-remitting multiple sclerosis (RRMS), according to nearly three years of follow-up in the VISIONARY-MS trial and its open-label extension (OLE). Developer Clene Nanomedicine plans to present full trial results at the upcoming ACTRIMS…

In people with multiple sclerosis (MS), disability worsening independent of relapse activity — commonly known as “silent progression” — tends to be accompanied by greater atrophy, or shrinkage, in the spinal cord, as well as a higher number of lesions with chronic inflammation, known as paramagnetic rim lesions or…

Treatment with Ocrevus (ocrelizumab) may stabilize disability progression in people with multiple sclerosis (MS) who have severe walking impairments — a patient group excluded from clinical trials supporting the therapy’s 2017 approval — a real-world analysis suggests. However, about half of those receiving Ocrevus in this study discontinued…

Adults with multiple sclerosis (MS) or traumatic brain injury report more cognitive fatigue, or exhaustion resulting from mental work, than do healthy individuals — regardless of the nature of the tasks being performed — a study found. However, cognitive fatigue built up at a similar rate among study participants…

The U.S. Food and Drug Administration (FDA) has cleared a Phase 2 clinical trial to test Kyverna Therapeutics‘ cell-based therapy candidate KYV-101 in people with treatment-resistant progressive multiple sclerosis (MS). Called KYSA-7 (NCT06138132), the open-label trial will enroll an estimated 12 patients with either primary progressive…

In people with a family history of multiple sclerosis (MS), exclusive breastfeeding in the first months of life may reduce the risk of developing the disease later on, whereas use of cow’s milk or formula may increase MS risk. That’s according to a new study on the potential impact…

An increasing number of people in western Norway have been diagnosed with relapsing-remitting multiple sclerosis (RRMS) after age 50 over the past century, according to a new population study. The rise was primarily driven by people being diagnosed at older ages, with the average age of onset rising from 28.6…

Living with the human immunodeficiency virus (HIV) is linked to a significantly lower rate of developing multiple sclerosis (MS) — including among people exposed to antiretroviral treatment, or medicines that can stop the HIV virus from replicating — a new study found. The rate of MS was particularly reduced…

An analysis of data covering nearly 200 people with multiple sclerosis (MS) found no association between dairy or gluten consumption and MS disease activity. While some specific diets for MS tend to restrict gluten and/or dairy, this study found that people who ate these dietary products were as…

Sudo Biosciences has raised $116 million in a Series B financing to support the clinical development of two inhibitors of the TYK2 enzyme for treating neurological conditions like multiple sclerosis (MS) and skin-related diseases. One of the TYK2 inhibitors, given orally, is designed to efficiently reach the brain…

Throughout 2023, Multiple Sclerosis News Today brought consistent coverage to our readers of the latest scientific research, developments in treatment, and clinical trials for multiple sclerosis (MS). Here is a list of the top 10 most-read stories we published last year, along with a brief description. We look…

The rate of brain atrophy, or shrinkage, and changes in brain lesion volume in the first years of treatment with Rebif (interferon beta-1a) may help predict which patients with early multiple sclerosis (MS) will receive a clinically definite diagnosis, a study suggests. The brain radiologic measures may also…

Sending SMS text messages to people with multiple sclerosis (MS) — with tips for fatigue self-management and to regularly check in on them — may be a feasible, acceptable, and engaging tool to help these patients manage disease-related fatigue, according to a pilot study. The findings also showed some…